Tang Yuqun, Tang Liangke, Du Haijian, Wu Chaosheng, Wang Zhuangxiong, Luo Guanshui, He Ke
Cancer Minimally Invasive Therapies Centre, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China.
Department of Thyroid and Breast Surgery, Southern Medical University, Hospital of Integrated Chinese and Western Medicine, Guangzhou, Guangdong, China.
Turk J Gastroenterol. 2024 Dec 16;36(4):255-262. doi: 10.5152/tjg.2024.24198.
BACKGROUND/AIMS: Recently, studies on FAM96B functions mainly focused on its role in maintaining the normal physiological function of cells. However, the clinical implications of FAM96B in hepatocellular carcinoma (HCC) are still unclear.
FAM96B mRNA expression was detected in human HCC tissues and the matched nontumorous tissues by quantitative real-time reverse transcription (qRT-PCR) and then validated in The Cancer Genome Atlas (TCGA) database. Immunohistochemistry assay (IHC) was performed on all 137 cases of HCC samples to examine the protein level of FAM96B. Subsequently, the associations between FAM96B expression and clinicopathological parameters and prognosis were further analyzed.
The mRNA level of FAM96B was found to be significantly lower in HCC tissues compared to non-tumorous tissues, as observed in both the local hospital and TCGA database.Immunohistochemistry assay analysis revealed a decrease in FAM96B expression in 78 out of 137 cases, which was significantly associated with larger tumor size, higher Barcelona clinic liver cancer or Child stage, and early distant metastasis. Patients with low FAM96B levels tended to have an unfavorable disease-free and overall survival. Moreover, FAM96B was identified as an independent predictor of patient prognosis in both univariate and multivariate survival analyses. Mechanistically, FAM96B was found to inhibit cancer progression by inducing apoptosis in liver cancer cells and inhibiting their growth.
Our findings provide the first evidence suggesting the involvement of FAM96B in the progression of HCC. Additionally, FAM96B could potentially serve as a marker for tumor recurrence and prognosis in HCC patients.
背景/目的：最近，关于FAM96B功能的研究主要集中在其在维持细胞正常生理功能中的作用。然而，FAM96B在肝细胞癌（HCC）中的临床意义仍不清楚。
通过定量实时逆转录（qRT-PCR）检测人HCC组织及配对的非肿瘤组织中FAM96B mRNA的表达，然后在癌症基因组图谱（TCGA）数据库中进行验证。对137例HCC样本进行免疫组织化学分析（IHC），以检测FAM96B的蛋白水平。随后，进一步分析FAM96B表达与临床病理参数及预后之间的关系。
在当地医院和TCGA数据库中均观察到，与非肿瘤组织相比，HCC组织中FAM96B的mRNA水平显著降低。免疫组织化学分析显示，137例中有78例FAM96B表达降低，这与肿瘤体积较大、巴塞罗那临床肝癌分期或Child分期较高以及早期远处转移显著相关。FAM96B水平低的患者往往无病生存期和总生存期不佳。此外，在单因素和多因素生存分析中，FAM96B均被确定为患者预后的独立预测因子。机制上，发现FAM96B通过诱导肝癌细胞凋亡并抑制其生长来抑制癌症进展。
我们的研究结果首次提供了证据，表明FAM96B参与了HCC的进展。此外，FAM96B可能作为HCC患者肿瘤复发和预后的标志物。
